Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY03017 SAD study in healthy adults
NCT06388551Phase 1Not yet recruiting
- Sponsor
- Luye Pharma Group
- Start
- May 2024
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Alzheimer's disease (AD), Parkinson's disease (PD) and schizophrenia comparing LY03017 with Placebo (2 arms). Primary endpoint: Incidence and severity of adverse events (AEs) and serious adverse events (SAEs) up to 216 hours. Planned start May 2024; status: not yet recruiting.
02
Drugs
LY03017
03
Conditions
Alzheimer's disease (AD)Parkinson's disease (PD)schizophrenia
Beyond the preview
Go deeper on NCT06388551.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06388551.